<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5965">
  <stage>Registered</stage>
  <submitdate>13/06/2016</submitdate>
  <approvaldate>13/06/2016</approvaldate>
  <nctid>NCT02826863</nctid>
  <trial_identification>
    <studytitle>A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome</studytitle>
    <scientifictitle>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZX008-1502</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dravet Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZX008 - 0.8 mg/kg/day
Treatment: drugs - ZX008 - 0.2 mg/kg/day
Treatment: drugs - Placebo

Experimental: Experimental: ZX008 - 0.8 mg/kg/day - ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.

Experimental: Experimental: ZX008 - 0.2 mg/kg/day - ZX008 is supplied as an oral solution in concentrations of 0.2 mg/kg/day ZX008 will be administered twice a day (BID) in equally divided doses with food.

Placebo Comparator: Placebo Comparator: Matching Placebo - Placebo will be administered twice a day (BID) in equally divided doses with food.


Treatment: drugs: ZX008 - 0.8 mg/kg/day
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.

Treatment: drugs: ZX008 - 0.2 mg/kg/day
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.

Treatment: drugs: Placebo
Placebo will be administered twice a day (BID) in equally divided doses with food.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in frequency of convulsive seizures in subjects receiving ZX008 0.8mg/kg/day compared to placebo - Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</outcome>
      <timepoint>Time between 6-week baseline assessment period and 14 week treatment and maintenance period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in frequency of convulsive seizures for subjects receiving ZX008 0.2mg/kg/day compared to placebo - Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</outcome>
      <timepoint>Time between 6-week baseline assessment period and 14 week treatment and maintenance period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a =40% or =50% reduction from baseline in convulsive seizure frequency and longest seizure-free interval in subjects receiving ZX008 0.2 and 0.8 mg/kg/day compared to placebo - Parent/caregiver seizure diary record will be used to assess frequency, type and duration of seizure activity</outcome>
      <timepoint>Time between 6-week baseline assessment period and combined 14 week treatment and maintenance period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency and severity of seizure activity for subjects receiving ZX008 0.2mg/kg/day and 0.8mg/kg/day compared to placebo - Seizure severity evaluated using parent/caregiver seizure diary to record frequency and severity of seizure activity</outcome>
      <timepoint>Time between 6-week baseline assessment period and 14 week treatment and maintenance period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of ZX008 0.2 and 0.8 mg/kg/day compared to placebo - Safety and tolerability will be evaluated by reported adverse events, laboratory parameters, physical and neurological examination, vital signs, electrocardiograms, echocardiograms, and body weight. (Cognitive function will be assessed using age-appropriate versions of the Brief Rating Inventory of Executive Function [BRIEF].)</outcome>
      <timepoint>Week 1 through Week 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key Inclusion Criteria

          -  Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day
             of the Screening Visit.

          -  Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely
             controlled by current antiepileptic drugs.

          -  Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior
             to screening.

          -  All medications or interventions for epilepsy (including KD and VNS) must be stable
             for at least 4 weeks prior to screening and are expected to remain stable throughout
             the study.

          -  Parent/caregiver is willing and able to be compliant with diary completion, visit
             schedule and study drug accountability.

        Key</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Pulmonary arterial hypertension.

          -  Current or past history of cardiovascular or cerebrovascular disease, such as cardiac
             valvulopathy, myocardial infarction or stroke.

          -  Current or past history of glaucoma.

          -  Moderate or severe hepatic impairment

          -  Receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine-oxidase inhibitors; medications that act via serotonin including serotonin
             reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist;
             cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates.

          -  Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or
             phenytoin, or has taken any of these within the past 30 days.

          -  Subject is unwilling to refrain from large or daily servings of grapefruits and/or
             Seville oranges, and their juices beginning with the Baseline Period and throughout
             the study.

          -  A clinically significant condition, or has had clinically relevant symptoms or a
             clinically significant illness in the 4 weeks prior to the Screening Visit, other than
             epilepsy, that would negatively impact study participation, collection of study data,
             or pose a risk to the subject.

          -  Currently receiving an investigational product.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>130</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Melbourne Brain Centre Austin Hospital - Melbourne</hospital>
    <hospital>Princes Margaret Hospital - Perth</hospital>
    <hospital>Children's Health Queensland Hospital and Health Service at Lady Cilento Children's Hospital - South Brisbane</hospital>
    <hospital>The Children's Hospital Westmead Dept. of Neurology and Neurosurgery - Westmead</hospital>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <postcode> - South Brisbane</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Dianalund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Radeberg (Sachsen)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>TÃ¼bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Vogtareuth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Mantova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the
      efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric
      and young adult subjects with Dravet syndrome. Subjects who qualify for the study will be
      randomized (1:1:1) in a double-blind manner to receive 1 of 2 doses of ZX008 or placebo. All
      subjects will be titrated to their randomized dose over a 14-day Titration Period. Following
      titration, subjects will continue treatment at their randomly assigned dose over a 12-week
      Maintenance Period. Total treatment time from the beginning of the Titration Period through
      the end of the Maintenance Period is 14 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02826863</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>ZX008 Clinical Trials Disclosure Desk</name>
      <address />
      <phone />
      <fax />
      <email>Medinfo@zogenix.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>